Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-infectives research. However, only one new TB drug has entered clinical practice in the past 40 years while drug resistance threatens to further destabilize the pandemic. Here, we review a brief history of TB drug development, focusing on the evolution of mechanism(s)-of-action studies and key conceptual barriers to rational, mechanism-based drugs.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: